TIM3 has emerged as a promising target for tumor immunotherapy, and a few antibodies against TIM3 have been reported to exhibit excellent effects in enhancing antiviral immune responses, stimulating IFN-mediated anti-tumor immunity of T cells, and counteracting tumor growth [27]. The gene discussed is HAVCR2; the disease is neoplasm.